For subscribers
Drug boosts treatment for blood cancer myeloma relapse patients
Sign up now: Get ST's newsletters delivered to your inbox
Professor Chng Wee Joo, director of the National University Cancer Institute, Singapore, and Madam Oh Hwee Hong, who is taking part in a trial for the myeloma drug carfilozomib.
ST PHOTO: DESMOND WEE
Cheryl Tee
Follow topic:
SINGAPORE - A drug, which aims to improve survival chances of relapsed myeloma patients, has been approved by the Health Sciences Authority (HSA).
Myeloma is an incurable blood cancer in the bone marrow or soft tissue. Symptoms include bone pain, kidney failure, and anaemia.
